Evidence map›Paper›PMID 37847239›Full record

ArticleMolecular cancer research : MCR2024

SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death.

Sheera R Rosenbaum, Signe Caksa, Casey D Stefanski, Isabella V Trachtenberg, Haley P Wilson, Nicole A Wilski, Connor A Ott, Timothy J Purwin, Jelan I Haj, Danielle Pomante and 4 more

Open access · greenAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. SpecificbioRxiv : the preprint server for biology · 2024
    Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Sheera R Rosenbaum *Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-7917-2969
Signe Caksa *Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-0133-0015
Casey D StefanskiDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-4943-6820
Isabella V TrachtenbergDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0009-0003-0341-2828
Haley P WilsonDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-2608-827X
Nicole A WilskiDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0003-0285-0853
Connor A OttDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0003-1374-6998
Timothy J PurwinDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-7053-8039
Jelan I HajDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0009-0001-3576-8955
Danielle PomanteDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0001-8660-8057
Daniel KotasDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0003-2310-0445
Inna ChervonevaDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-9104-4505
Claudia CapparelliDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0001-9834-8539
Andrew E AplinDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-2734-3244
Thomas Jefferson University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Claudio Guillermo Giraudo · 1995 to 2026
$94.8M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI XU, XIAOWEI · 2008 to 2023
$37.1M
Targeted therapies in mutant BRAF melanomaR01CA182635 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2014 to 2024
$3.4M
Training Grant in Cellular, Biochemical and Molecular SciencesT32GM144302 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI DIANE E MERRY, PHILIP B WEDEGAERTNER · 2022 to 2026
$2.0M
Mutant BRAF-regulated transcription factors in melanoma progressionR01CA196278 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2015 to 2019
$1.8M
Training Program in Cancer BiologyT32CA236736 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC, LANGUINO, LUCIA R. · 2019 to 2023
$1.1M
Training Program in Cellular, Biochemical, and Molecular SciencesT32GM100836 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI BENOVIC, JEFFREY L · 2012 to 2016
$809k
Tumor Intrinsic Regulation of Immune Evasion Pathways in Breast CancerK00CA245552 · NCI · UNIVERSITY OF COLORADO DENVER · PI ROSENBAUM, SHEERA · 2021 to 2024
$453k
Tumor Intrinsic Regulation of Immune Evasion Pathways in MelanomaF99CA245552 · NCI · THOMAS JEFFERSON UNIVERSITY · PI ROSENBAUM, SHEERA · 2019 to 2020
$92k
NCI NIH HHS F99 CA245552NCI NIH HHS K00 CA245552NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA182635NCI NIH HHS R01 CA196278NCI NIH HHS T32 CA236736NIGMS NIH HHS T32 GM100836NIGMS NIH HHS T32 GM144302
6 · The paper itself

Abstract

The transcription factor, SOX10, plays an important role in the differentiation of neural crest precursors to the melanocytic lineage. Malignant transformation of melanocytes leads to the development of melanoma, and SOX10 promotes melanoma cell proliferation and tumor formation. SOX10 expression in melanomas is heterogeneous, and loss of SOX10 causes a phenotypic switch toward an invasive, mesenchymal-like cell state and therapy resistance; hence, strategies to target SOX10-deficient cells are an active area of investigation. The impact of cell state and SOX10 expression on antitumor immunity is not well understood but will likely have important implications for immunotherapeutic interventions. To this end, we tested whether SOX10 status affects the response to CD8+ T cell-mediated killing and T cell-secreted cytokines, TNFα and IFNγ, which are critical effectors in the cytotoxic killing of cancer cells. We observed that genetic ablation of SOX10 rendered melanoma cells more sensitive to CD8+ T cell-mediated killing and cell death induction by either TNFα or IFNγ. Cytokine-mediated cell death in SOX10-deficient cells was associated with features of caspase-dependent pyroptosis, an inflammatory form of cell death that has the potential to increase immune responses. IMPLICATIONS: These data support a role for SOX10 expression altering the response to T cell-mediated cell death and contribute to a broader understanding of the interaction between immune cells and melanoma cells.

Indexed as

MelanomaCell DeathCytokinesHumansSOXE Transcription FactorsTumor Necrosis Factor-alphaCytokinesSOX10 protein, humanSOXE Transcription FactorsTumor Necrosis Factor-alpha

Identifiers

PMID37847239
PMCPMC10842433
OpenAlexW4387692349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.